NCT04492618View on ClinicalTrials.gov

Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 29, 2020

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions
Necrobiosis Lipoidica
Interventions
DRUG

Ruxolitinib

Ruxolitinib cream 1.5%, topical application will be used twice daily on lesions of Necrobiosis Lipoidica

Trial Locations (1)

85259

Mayo Clinic in Arizona, Scottsdale

All Listed Sponsors
lead

Aaron R. Mangold

OTHER

NCT04492618 - Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica | Biotech Hunter | Biotech Hunter